USWeb is an Internet services firm serving medium-size organizations to Fortune 100 corporations. USWeb offers its clients Internet marketing strategies and systems.
The company, founded in 1995, has offices across the United States. Their staff of experienced, qualified and professional Internet consultants designs, develops, and implements custom web systems and integrated online marketing solutions that focus on brand awareness, audience development, and customer retention.
Successful online marketing depends largely on your ability to identify the marketing opportunities that provide the best opportunity to reach your target audience in a scalable and cost effective manner. Research shows that 70 to 80% of Internet users rely on search engines to find relevant content. Competition is fierce at the top of the search engines.
USWeb offers search engine marketing services designed to get your site noticed when potential buyers are looking for the products and services you have to offer. Search Engine Optimization, PPC Bid Management, and Trusted Feed are the services USWeb supplies to target and drive self-qualified prospects to your website.
Saturday, January 06, 2007
Blind Mice Regain Sight
Scientists say they've restored the vision of blind mice by introducing light-sensitive cells into their retinas. These are not stem cells, but come from a later stage of cell development when stem cells have already determined what type of cells they will be. In this case we're talking about the rod-and-cone photoreceptors the eye uses to sense light.
"We think this is a major breakthrough because it shows what can be achieved," said study lead researcher Dr. Robert MacLaren, a consultant vitreoretinal surgeon at Moorfields Eye Hospital and a clinician scientist at the University of London, in England.
Scientists have tried to use stem cells before to restore sight, but their efforts failed. Dr. MacLaren believes that timing is crucial to success. He transplanted the photreceptors from newborn mice into the blind mice's retinas (they are looking for a way to use adult stem cells) and the retinas accepted these photoreceptors and made connections to the mice's brains. The mice are receptive to light.
"These cells were transplanted extremely quickly (i.e., 30 minutes out of their normal environment)," MacLaren said. This rapid transfer, plus their positioning in a conducive retinal environment, means that the cells "were able to form quick connections with host cells," he said.
This certainly sounds hopeful. If they can learn how to use adult stem cells they won't need embryonic stem cells.
Dale L. Edwards
"We think this is a major breakthrough because it shows what can be achieved," said study lead researcher Dr. Robert MacLaren, a consultant vitreoretinal surgeon at Moorfields Eye Hospital and a clinician scientist at the University of London, in England.
Scientists have tried to use stem cells before to restore sight, but their efforts failed. Dr. MacLaren believes that timing is crucial to success. He transplanted the photreceptors from newborn mice into the blind mice's retinas (they are looking for a way to use adult stem cells) and the retinas accepted these photoreceptors and made connections to the mice's brains. The mice are receptive to light.
"These cells were transplanted extremely quickly (i.e., 30 minutes out of their normal environment)," MacLaren said. This rapid transfer, plus their positioning in a conducive retinal environment, means that the cells "were able to form quick connections with host cells," he said.
This certainly sounds hopeful. If they can learn how to use adult stem cells they won't need embryonic stem cells.
Dale L. Edwards
New Treatment for Diabetics
Macular edema is a potentially blinding disease that can develope in diabetics. In macular edema fluid accumulates in the macula, a part of the retina, which is responsible for central vision.
An increase in VEGF, a growth factor, appears to play a role in macular edema. Ranibizumab, a VEGF blocker, given as ocular injections shows promise in the treatment of macular edema and macular degeneration. An earlier study showed an improvement in patients with macular degeneration.
"The results are impressive," lead author Dr. Quan Dong Nguyen, from Johns Hopkins Wilmer Eye Institute in Baltimore, said in a statement. However, "we will not know until we begin a larger clinical trial what the long-term benefits of the drug might be."
Nguyen's team investigated the effects of ranibizumab in 10 patients with diabetic macular edema. The subjects were given intraocular injections of ranibizumab at the start of the study and at 1, 2, 4, and 6 months.
At the 7-month checkup, researchers noted a significant drop in macular thickness and improvement in visual acuity in study subjects.
There appear to be no side effects from this injection. More studies are planned.
Dale L. Edwards
An increase in VEGF, a growth factor, appears to play a role in macular edema. Ranibizumab, a VEGF blocker, given as ocular injections shows promise in the treatment of macular edema and macular degeneration. An earlier study showed an improvement in patients with macular degeneration.
"The results are impressive," lead author Dr. Quan Dong Nguyen, from Johns Hopkins Wilmer Eye Institute in Baltimore, said in a statement. However, "we will not know until we begin a larger clinical trial what the long-term benefits of the drug might be."
Nguyen's team investigated the effects of ranibizumab in 10 patients with diabetic macular edema. The subjects were given intraocular injections of ranibizumab at the start of the study and at 1, 2, 4, and 6 months.
At the 7-month checkup, researchers noted a significant drop in macular thickness and improvement in visual acuity in study subjects.
There appear to be no side effects from this injection. More studies are planned.
Dale L. Edwards
Subscribe to:
Posts (Atom)